We've updated our Privacy Policy. Questions? Email us any time at privacy@ground.newsWe've updated our Privacy Policy with additional info on research surveys, our browser extension, cookie management, and ad performance measurement. Questions? Email us any time at privacy@ground.news

Published 10 days ago • loading... • Updated 10 days ago

RXR Nuclear Receptor Agonists Promote Clearance of Alpha-Synuclein in Cellular Models

Summary by The Hamilton Spectator

SPRING, Texas, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas, announced today the presentation of new research demonstrating that IRX4204, the company’s phase II clinical stage highly selective RXR nuclear…

6 Articles

6 Articles

St Catharines Standard

+5 Reposted by 5 other sources

RXR Nuclear Receptor Agonists Promote Clearance of Alpha-Synuclein in Cellular Models

SPRING, Texas, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas, announced today the presentation of new research demonstrating that IRX4204, the company’s phase II clinical stage highly selective RXR nuclear…

10 days ago·Welland, Canada

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources6

Leaning Left4Leaning Right2Center0Last Updated10 days agoBias Distribution

67% Left

Bias Distribution

67% of the sources lean Left

67% Left

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Hamilton Spectator broke the news in Hamilton, Canada 10 days ago on Wednesday, August 5, 2026.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics